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Abstract
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of Type 2 Diabetes
(T2DM), which requires daily subcutaneous administration. In T2DM patients, GLP-1 administration is reported to reduce
glycaemia and HbA1c in association with a modest, but significant weight loss. The aim of present study was to characterize
the site-specific profile and metabolic effects of Ex-4 levels expressed from salivary glands (SG) in vivo, following adeno-
associated virus-mediated (AAV) gene therapy in two different animal models of obesity prone to impaired glucose
tolerance and T2DM, specifically, Zucker fa/fa rats and high fed diet (HFD) mice. Following percutaneous injection of AAV5
into the salivary glands, biologically active Ex-4 was detected in the blood of both animal models and expression persisted
in salivary gland ductal cell until the end of the study. In treated mice, Ex-4 levels averaged 138.9642.3 pmol/L on week 6
and in treated rats, mean circulating Ex-4 levels were 238.2672 pmol/L on week 4 and continued to increase through week
8. Expression of Ex-4 resulted in a significant decreased weight gain in both mice and rats, significant improvement in
glycemic control and/or insulin sensitivity as well as visceral adipose tissue adipokine profile. In conclusion, these results
suggest that sustained site-specific expression of Ex-4 following AAV5-mediated gene therapy is feasible and may be useful
in the treatment of obesity as well as trigger improved metabolic profile.
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Introduction
Glucagon-like peptide 1 (GLP-1), a gastrointestinal hormone
mainly produced in a nutrient-dependent manner [1], enhances
glucose-dependent insulin secretion and inhibits food intake,
gastric emptying, and glucagon release, thus promoting the
maintenance of normal glucose homeostasis [2]. A small, but
significant, defect in oral glucose load and mixed meal stimulated
GLP-1 secretion has been observed in T2DM [3,4]. In T2DM
patients, GLP-1 chronic administration reduces fasting and
postprandial blood glucose and decreases HbA1c in association
with a modest, but significant weight loss [5]. The short half-life
of GLP-1, due to rapid inactivation mainly catalyzed by
dipeptidyl-peptidase-4 (DDP-4), has engendered interest in the
development of more stable longer-acting GLP-1 receptor
agonists (GLP-1 RA) for the treatment of T2DM. Exendin-4
(Ex-4), is a natural GLP-1 RA, which because of its molecular
structure, is considerably more resistant than native GLP-1 to
degradation by DPP-4 [6]. Exenatide (the synthetic form of Ex-4)
significantly improves glycaemic control and causes progressive
weight loss in T2DM patients, requiring a twice daily subcuta-
neous administration [7,8].
Gene therapy offers the possibility of a long-term expression in
the treatment of many chronic diseases, including T2DM [9].
Adenoviral and plasmid-based vectors have been used to express
GLP-1 RA in several tissues but have not resulted in long term
effects either as a result of low or transient expression [10–16].
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40074
While effective in animal models, the inherent risk profile related
to systemic delivery of vectors supported site-specific gene
therapeutic approaches as an appealing alternative [17].
Recently, Adeno-associated Viruses (AAVs) have advanced to
the forefront of gene therapy, due to their ability to achieve long-
term transgene expression in vivo and low immunogenicity [18–
21]. Several Phase I/II clinical trials support a good overall safety
profile for AAV vectors and little associated toxicity in humans
[22–26]. Over 100 AAV isolates have been reported, biochemical
and molecular characterization suggests that some exhibit different
tissue tropism, persistence, and transduction efficiency [27].
Among AAVs, serotype 5 (AAV5) has demonstrated enhanced
gene transfer activity in lung, eye and CNS as well as rodent
salivary glands (SG) [28].
SG are recognized as a useful depot organ in gene therapy,
having several important features of other endocrine glands, such
as high protein production and ability to secrete proteins into the
bloodstream [29]. It has been previously reported that SGs are
able to produce pharmacological levels of growth hormone and
parathyroid hormone following transduction with recombinant
viral vectors [30,31]. A phase I clinical trial targeting gene
transfer to the salivary glands for treating radiation induced
xerostomia was initiated and a total of 11 patients have been
treated with all reporting tolerance of the vector and procedure
[32].
In the present study we have characterized metabolic effects
and site-specific secretion profile of sustained Ex-4 expression
from the SG of both a polygenic and monogenic animal models
of obesity prone to impaired glucose tolerance and T2DM. Ex-4
expression resulted in a significant decrease in weight gain in
both models, improved glycemic control and/or insulin sensitiv-
ity and visceral adipose tissue adipokine profile, thus suggesting
long-term benefit following sustained expression.
Materials and Methods
Construction, Preparation, and Quantification of AAV5
Vectors Carrying the Ex-4 Minigene
Recombinant AAV particles were produced using a four-
plasmid procedure as previously described in Di Pasquale G et al
[33]. The AAV5 vector cassette was designed to contain the
cytomegalovirus (CMV) promoter, the mouse nerve growth factor
(NGF) signal peptide, which has been shown to mediate secretory
expression of polypeptides in vitro and in vivo [34] and the
minigene coding for Ex-4. Briefly, semiconfluent human embry-
onic kidney 293T cells obtained from the American Type Culture
Collection (ATCC, Manassas, VA) were transfected by calcium
phosphate with four plasmids: an adenovirus helper plasmid
(pAd12) containing VA RNA and coding for the E2 and E4
proteins; two AAV helper plasmids containing either the AAV2rep
or the AAV5 capsid gene and a vector plasmid including the AAV
inverted terminal repeats flanking the Ex-4 expression cassette.
The cells were harvested 48 hours post-transfection and a crude
viral lysate was obtained after three freeze-thaw cycles. The
clarified lysate (obtained by further low-speed centrifugation) was
treated with 0.5% deoxycolic acid (DOC) and 100 U/ml DNase
(Benzonase) for 30 minutes at 37uC. After purification of viruses by
CsCl gradient ultracentrifugation, vector titer was determined by
quantitative real-time PCR (qPCR) (Applied Biosystems, Foster
City, CA). Immediately before experiments, vector doses were
dialyzed against 0.9% NaCl.
Cell Cultures and in vitro Transfection
The generated recombinant AAV5 virus encoding the Ex-4
minigene was then tested in vitro. 293T human renal epithelial
cells were grown at 37uC under a 5% CO2 humidified atmosphere
in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U of penicillin/
Figure 1. Epifluorescence microscopic image of salivary glands by immunohistochemical assay against Exendin-4, in AAV-5
Exendin-4 treated (Fig. A) and control High Fat-Diet mice (Fig. B); barr = 20 mm. The immunoreaction products are observed under a Zeiss
Axioskop microscope at x40 magnification.
doi:10.1371/journal.pone.0040074.g001
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ml, and 0.1 mg of streptomycin/ml. 293T cells were transfected
with the AAV5 Ex-4 vector at 103 DNase Resistant Particles
(DRP)/ml per cell. Ex-4 levels into the culture medium was
assayed using a specific enzyme immunoassay kit (Phoenix Europe
GmbH, Germany).
For in vitro bioactivity assay, supernatant medium from 293T
cells transduced with AAV5 Ex-4 (after 96 hours of incubation)
was tested on Chinese hamster ovary cell line obtained from
American Type Culture Collection (ATCC, Manassas, VA) stably
transfected with rat GLP-1 receptor (CHO-GLP1R) accordingly
to previously reported study from Egan JM et al [35].
Animal Models
Animal studies were carried out in strict accordance with the
European Communities Council Directive of 24 November 1986
(86/609/EEC) for experimental animal care. The study protocol
was approved by the Italian National Health Institute Committee
Figure 2. Weight gain of High Fat Diet mice (n=20) and Zucker fa/fa rats (n=10) following vector administration. The graphs
represent the average values (g) 6 Standard Error (SE). Weight gain is expressed as difference (g) between weight at study point and baseline value.
(A) Weight gain of High Fat-Diet mice. Each group was composed of ten mice. ¥ = p,0.01. (B) Weight gain in Zucker fa/fa rats. Each group was
composed of five rats. * = p,0.05.
doi:10.1371/journal.pone.0040074.g002
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on Animal experiments. All surgeries were performed under
anesthesia, and all efforts were made to minimize suffering.
Male 4 week old CD1 mice (n = 20) were purchased from
Harlan Laboratories (Udine, Italy), housed at five animals per
group and fed High Fat Diet ad libitum (Dottori Piccioni
Laboratories Srl, Milan, Italy). The HFD supplied 60% of energy
as fat and 20% as carbohydrate. Fatty acid composition was as
follows: 42.0% saturated fatty acids (palmitic and stearic acids),
43% monounsaturated fatty acids (oleic acid), and 15% polyun-
saturated fatty acid (linoleic acid and linolenic acid). The HFD
contained 300 mg cholesterol/kg and its energy density was
21.10 kJ/g. The HFD fed mice are recognized as an efficient and
robust animal model for obesity, early prone to impaired glucose
tolerance and T2DM development [36].
Male Zucker fa/fa rats (n = 10) purchased from Charles River
laboratories (Lecco, Italy) were housed in single cage and received
standard chow ad libitum (Purina Rodents Laboratory Diet). Zucker
fa/fa rats are conversely a spontaneous monogenic obesity model,
characterized by a missense mutation on the leptin receptor gene
[37].
Submandibulary salivary glands of 8 week old HFD mice
(n = 10) and of 9 week old Zucker fa/fa rats (n = 5) were
transduced by single percutaneous injection of 50 ml of AAV5
Ex-4 (561012 DRP/ml) vector. Control animals (n = 10 HFD
mice; n = 5 Zucker fa/fa rats) received 50 ml of AAV-5 vector
devoid of Ex-4 transgene (empty vector). On a weekly basis weight,
food, water intake, urine volume, glycaemia were monitored
throughout the study. In order to evaluate effects of treatment on
short term food consumption, a 120 minutes food intake
evaluation, after overnight fasting, was also performed in rats. A
fixed amount of standard chow was given in individual cages and
rodents food intake (evaluated as the difference between the
baseline amount and the residual food, including spillage) was
measured every 15 minutes.
An intraperitoneal insulin tolerance test (ITT) was performed in
HFD mice, 6 weeks following vector administration. Each animal
was fasted for 4 hours. Following intraperitoneal insulin (Humulin
R Regular, Lilly) injection (1 UI/kg), blood samples from the
lateral tail vein were collected to measure glycaemia at 0, 15, 30,
60, 90 and 120 minutes. The glucose areas under the curve (AUC,
mM per minute) were calculated according to formula:
AUC0–120 min = (G0+ G15 ) x 15/2+(G15+ G30 ) x 15/2+(G30+
G60 ) x 30/2+(G60+ G120 ) x 60/2.
Blood samples were withdrawn at baseline and week 6 in HFD
mice in order to detect Ex-4, glycaemia, insulinemia, HbA1c,
leptin and adiponectin circulating levels and at 0, 4, and 8 week in
Zucker fa/fa rats to detect Ex-4 and glucose values. HbA1c and
insulinemia were determined at baseline and 8 weeks after vector
administration. Blood samples were obtained through jugular
sampling conducted in isoflurane-anesthetized animals. At study
end, rats and mice were respectively euthanized by CO2 (80%)
inhalation.
SG, liver, spleen, and pancreas tissues were collected for DNA
extraction and vector distribution assay.
Ex-4 Assay
Ex-4 exhibits 53% structural homology to native GLP-1.
Circulating Ex-4 levels were determined by a specific enzyme
immunoassay kit (Phoenix Europe GmbH, Germany), unable to
detect endogenous GLP-1 values, according to the manufactur-
ers’ instructions. Minimum detectable concentration was
2.6 pmol/L.
Vector Biodistribution
In order to assess vector biodistribution at the end point of the
study, a DNA isolation kit was used to purify total genomic DNA
from SG, liver, spleen and pancreas (Wizard DNA purification kit,
Promega Corporation, Madison, WI, USA). Quantitative PCR
amplification (20 ml final volume) of genomic DNA (100 ng) was
performed with ABI PRISM 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA) by using the SYBR Green
PCR Master Mix and a specific 59 and 39 primer pair appropriate
(0.3 mM; CMV forward 59-CATCTACGTATTAGTCATCGC-
TATTACCAT- 39, CMV reverse 59-TGGAAATCCCCGT-
GAGTCA-39) for CMV promoter. Amplification and detection
were performed with ABI Prism 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA). A PCR cycling reaction
involved an initial hold at 95u for 10 minutes, followed by cycling
conditions of 95uC for 15 seconds, 60uC for 1 min for 40 cycles.
The viral DNA in each sample was quantified by comparing the
fluorescence amplification profiles with a set of DNA standards
using AAV5 vector and 100 ng of genomic DNA of untreated
animals for each specific tissue. Each measurement was carried out
in duplicate. Data are expressed in copies of AAV5 for 100 ng of
genomic DNA.
Salivary Glands Immunohistochemical Assay
At the end of the study, SG were removed from treated (n = 5)
and control (n = 5) HFD mice, fixed in 4% paraformaldehyde for
24 hours at room temperature, cryoprotected in 30% sucrose in
phosphate-buffered saline (PBS) for approximately 12 hours at 4uC
Table 1. Baseline characteristics of High Fat-Diet (HFD) fed mice and Zucker fa/fa rats (control and AAV5 Ex-4 treated animals).
Control HFD
mice
AAV5 Ex-4 HFD
mice p*
Control Zucker
fa/fa rats
AAV5 Ex-4 Zucker
fa/fa rats p*
n 10 10 5 5
Weight (g) 23.361.9 23.061.6 p.0.05 290.6626.2 294.2628.5 p.0.05
Fasting glycemia (mmol/L) 4.660.8 4.760.6 p.0.05 5.160.8 5.360.8 p.0.05
Insulinemia (pmol/L) 82.165.3 86.067.2 p.0.05 1456.36182.2 1528.56168 p.0.05
HOMA-IR index (units) 2.860.3 3.060.4 p.0.05 55.165.6 60.067.2 p.0.05
HbA1c (%) ,4 ,4 p.0.05 4.260.1 4.160.2 p.0.05
Glycosuria (number positive) 0 0 0 0
Daily food intake (g) 2.960.8 3.160.5 p.0.05 27.862.8 29.063.0 p.0.05
*Control in comparison to AAV5 Ex-4 HFD mice and control versus AAV5 Ex-4 Zucker fa/fa rats, respectively.
doi:10.1371/journal.pone.0040074.t001
Sustained AAV5-Mediated Exendin-4 Secretion
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and then embedded in Killik cryostat embedding medium (Bio-
Optica, Milan Italy). Cryosections, 10 mm thick, were collected on
polylysine-coated slides.
The slides were pre-incubated in 0.5% Triton (Sigma Aldrich,
Milan, Italy) and 1.5% Bovine Serum Albumin (BSA) (Sigma
Aldrich, Milan, Italy) in PBS for 15 minutes at room temperature
to saturate non specific sites. Then the sections were incubated 24
hours at 4uC with primary antibody against Ex-4 (Phoenix Europe
GmbH, Germany) at final dilution of 1:50.
Subsequently, the sections were incubated with an Alexa Fluor
488 secondary Donkey anti Rabbit antibody (Invitrogen, San
Diego, CA, USA) at a final dilution of 1:333 for 2 hours at room
temperature. The immunoreaction products were observed under
an epifluorescence Zeiss Axioskop microscope (Zeiss, Germany) at
x40 magnification.
Adipokines Circulating Levels Assay
Serum leptin and adiponectin levels were assayed only in the
polygenic model of obesity prone to im paired glucose tolerance
and T2DM such as HFD mice using commercially available kit
according to manufacturer’s instructions. Sandwich enzyme
immunoassay (ELISA) was used for the quantitative measurement
of mouse proteins (Biovendor, Heidelberg, Germany and B-Bridge
International Inc., CA, USA, for leptin and adiponectin respec-
tively). Intra- and inter-assay coefficient of variation were less than
5%.
Visceral Adipose Tissue Adipokines Profile: RNA
Extraction and Real Time PCR Determinations
Total RNA was extracted from 50 mg of mice visceral adipose
tissue. Briefly, tissue samples were collected, immediately snap
frozen in liquid nitrogen and disrupted by homogenization in
QIAzol Lysis Reagent using the TissueLyser (QIAGEN GmbH,
Hilden, Germany). RNA was extracted using RNeasy Lipid Tissue
Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the
manufacturer’s instructions. One mg of RNA was treated with
TURBO DNA-freeTM DNase Kit (Ambion, Inc, Austin, TX,
USA) and reverse-transcribed into cDNA for 1 h at 37uC in a
50 ml reaction containing 16 RT buffer, 150 ng random
hexamers, 0.5 mmol/l dNTPs, 20 units of RNAsin Ribonuclease
Inhibitor (Promega Corporation, Madison, WI, USA) and 200
units of M-MLV RT (Promega Corporation, Madison, WI, USA).
Real Time quantitative PCR was carried out on DNA Engine
OpticonTM 2 Continuous Fluorescence Detection System (MJ
Research, MA, USA), using PlatinumH SYBRH Green qPCR
SuperMix-UDG (Invitrogen Corporation, CA, USA) and 300 nM
specific primers for each gene : 18 s forward 59-CGG CTA CCA
CAT CCA AGG AA-39, reverse 59-GCT GGA ATT ACC GCG
GCT-39; leptin forward: 59-TCC AGA AAG TCC AGG ATG
ACA C-39, reverse: 59-CAC ATT TTG GGA AGG CAG G-39;
adiponectin forward: 59-ACA ATG GCA CAC CAG GCC GTG
A-39, reverse: AGC GGC TTC TCC AGG CTC TCC TTT-39.
Each cDNA sample was assayed in duplicate and a no template
control was included in every reaction. For each sample, gene
expression values were normalized by 18s RNA content and
reported as AU ratio.
Blood and Urine Analysis, HOMA-IR Index
Glycaemic values were determined in the morning, after
overnight fasting. Blood was obtained via tail vein and tested,
using an Accu-Chek Aviva Nano meter (Roche). HbA1c
percentage values were measured on 5 ml of whole blood using
an A1CNow + test Kit (Bayer). Insulin levels were determined
using a commercially available insulin RIA kit (Linco Research,
Figure 3. Daily and short term food intake (average values ± Standard Error). (A) Daily food intake in High Fat-Diet mice. Each group was
composed of ten mice. (B) Daily food intake in Zucker fa/fa rats. Each group was composed of five rats. * p,0.05. (C) Short term food intake in Zucker
fa/fa rats 4 weeks after vector administration. Each group was composed of five rats. ¥ = p,0.01.
doi:10.1371/journal.pone.0040074.g003
Figure 4. Intraperitoneal insulin tolerance test at week 6, in High Fat-Diet mice. Each group was composed of ten mice and the graphs
represent the average glycaemic values (mmol/L) 6 Standard Error (SE). * = p,0.05.
doi:10.1371/journal.pone.0040074.g004
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Inc., St. Charles, MO); the intra-assay coefficient of variation was
1.4%. Insulin resistance was evaluated by the homeostasis model
assessment of insulin resistance (HOMA-IR) index calculated as:
(fasting glycaemia, mmol/L x fasting serum insulin, pmol/L/135)
[38]. Urine analysis was performed by a colorimetric method
(AUTION Sticks 10TA; Arkray, Inc, Kyoto, Japan) in order to
detect glucose levels.
Statistical Analysis
The statistical significance of differences between experimental
and control groups was analyzed by Student’s t-test. p,0.05 was
considered statistically significant. Values are presented as mean6
standard error (SE).
Results
Expression of Immunoreactive and Biologically Active Ex-
4 in vitro and in vivo
In order to facilitate processing and secretion, Ex-4 coding
sequence was linked to the secretory signal peptide from nerve
growth factor (NGF), which was modified to be cleaved by the
furin protease. Initial in vitro experiments suggested the chimeric
protein could be secreted from cells in culture. Media collected
from AAV5 Ex-4 transduced 293T cells produced an average of
38.3610.4 pmol/L when assayed for Ex-4 biological activity on
Chinese hamster ovary cell line stably transfected with rat GLP-1
receptor (CHO/GLP-1R). The furin overexpression by transfec-
tion of a plasmid encoding the protease, increased the active Ex-4
in the medium to 75.6611.0 pmol/L.
Ex-4 secretion was evaluated in vivo in two different animal
models of obesity prone to impaired glucose tolerance and T2DM,
following single 50 ul (561012 DRP/ml) vector administration
into their SG. Our initial in vivo experiments suggested that like
erythropoietin (27), NGF-Ex-4 can be produced by the salivary
glands and will traffic through the cell via the endocrine pathway
resulting in circulating serum levels. In AAV5 Ex-4 HFD mice
(n = 10), Ex-4 levels averaged 138.9642.3 pmol/L at week 6,
when assayed by a specific Enzyme Immunoassay (EIA) kit. In
AAV5 Ex-4 Zucker fa/fa rats (n = 5), mean circulating Ex-4 level
was 238.2672 pmol/L at week 4 and increased to 3.25 nmol/L at
week 8. In control animals, average circulating Ex-4 levels resulted
less than 2.6 pmol/L, thus above detection limit, at week 6 in mice
and both at week 4 and 8 in rats.
Biological activity of Ex-4 was also confirmed on CHO/GLP-
1R cells (data not shown).
Vector Biodistribution and Expression in vivo
In order to assess vector biodistribution, DNA samples were
collected from the SG, liver, spleen and pancreas of HFD mice
(n = 5 AAV5 Ex-4 treated and n = 5 naı¨ve mice) at the end of the
study and vector copy number was determined by quantitative
Polymerase Chain Reaction (qPCR) amplification using specific
primers for the CMV promoter. Naı¨ve animals yielded back-
ground levels of 55629 copies/100 ng of DNA extracted from
SG. In AAV5 Ex-4 HFD mice, a 60-fold increase in vector copy
number was detected in SG (355161618 copies/100 ng of DNA).
The vector copy number detected in other tissues such as liver
(154656 copies/100 ng of DNA), spleen (65623 copies/100 ng of
extracted DNA) and pancreas (104647 copies/100 ng of DNA)
were at or near background levels.
Expression was also confirmed by immunohistochemical
staining for Ex-4 in SG sections from AAV5 Ex-4 (n = 5) and
control (n = 5) HFD mice euthanized at week 6. Ex-4 expression is
observed only in the AAV5 Ex-4 treated group. Only salivary
ductal cells revealed positive staining, which is consistent with the
tissue tropism of the AAV5 vector (Figure 1B).
Reduced Weight Gain in Ex-4 Treated HFD Mice and
Zucker fa/fa Rats
At baseline HFD mice treated with AAV5-Ex 4 vector were not
significantly different from control animals with respect to weight,
fasting glucose and insulinemia, HOMA-IR index, HbA1c,
glycosuria or daily food intake (Table 1). Both case and control
animals received High Fat diet ad libitum and continued to gain
weight throughout the study. However, at termination of the study
(week 6), AAV5 Ex-4 HFD mice had a significantly lower weight
gain in comparison to control animals (Figure 2A).
Zucker fa/fa rats are a spontaneous monogenic model of obesity
as a result of a dysfunctional leptin receptor. At baseline, AAV5
Ex-4 rats also were not significantly different from control animals
with respect to weight, fasting glucose and insulinemia, HOMA-
IR index, HbA1c levels, glycosuria, and daily food intake
(Table 1). These animals received standard chow ad libitum
throughout the study, which was terminated 8 weeks after vector
administration. At week 5, AAV5 Ex-4 rats had a statistically
significant lower weight gain compared with control animals,
which persisted for the duration of the study (Figure 2B).
Differences in daily food intake between treated and control
animals were detected only transiently in rats (Figure 3B), but not
in mice (Figure 3A). In AAV5 Ex-4 rats, daily food consumption
Table 2. Final characteristics of High Fat-Diet (HFD) fed mice and Zucker fa/fa rats (control and AAV5 Ex-4 treated animals).
Control HFD
mice
AAV5 Ex-4
HFD mice p*
Control Zucker
fa/fa rats
AAV5 Ex-4 Zucker
fa/fa rats p*
n 10 10 5 5
Weight gain (g) 19.561.9 16.562.7 p,0.01 241.4622.5 222623.4 p,0.05
Fasting glycemia (mmol/L) 4.960.9 4.860.7 p.0.05 5.760.4 5.660.5 p.0.05
Insulinemia (pmol/L) 150.666.1 126.364.0 p,0.01 3862.96320.3 3164.86265.0 p,0.05
HOMA-IR index (units) 5.560.4 4.560.4 p.0.05 163.1615.0 131.2611.2 p,0.05
HbA1c (%) 4.260.2 4.160.2 p.0.05 5.060.1 4.760.1 p,0.05
Glycosuria (number
positive)
0 0 4 0 p,0.05
Daily food intake (g) 4.360.3 4.660.3 p.0.05 21.262.1 21.361.9 p.0.05
*Control in comparison to AAV5 Ex-4 HFD mice and control versus AAV5 Ex-4 Zucker fa/fa rats, respectively.
doi:10.1371/journal.pone.0040074.t002
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was significantly lower at week 4 compared with controls.
Similarly, short-term food intake monitoring was also reduced in
the AAV5 Ex-4 treated rats compared with control animals by 75
minutes (Figure 3C).
Reduced Leptin Levels in AAV-5 Ex-4 Treated Mice
In addition to reduced weight gain, AAV5 Ex-4 treated mice
had significant lower circulating levels of leptin (week 6) compared
with control animals (2.2460.39 versus 5.8961.07 ng/ml;
p,0.01). In contrast, no significant difference in adiponectin
levels were observed (9.7560.69 versus 10.5760.97 mg/l;
P = NS). The reduction in leptin circulating levels correlated with
a significant reduction in visceral adipose tissue leptin mRNA
expression compared with control animals (3.4360.48 versus
8.2860.72 Arbitrary Unit, AU; p,0.01). No difference in visceral
adipose tissue adiponectin mRNA expression (8.2860.72 versus
8.9561.8 AU; P = NS) was detected.
Improved Glycemic Control and/or Insulin Sensitivity
both in Treated HFD Mice and Zucker fa/fa Rats
Mice feed a high fat diet will develop T2DM after 12 weeks.
Accordingly, the model animals exhibited throughout the study a
mild increase of glycemia and HbA1c, high serum insulin levels
and HOMA-IR index. In order to better understand early effects
of AAV5 Ex-4 treatment on the development of insulin resistance,
insulin tolerance was tested (ITT) following an intraperitoneal
insulin injection. At week 6, AAV5 Ex-4 mice showed a greater
insulin-induced reduction in glycaemia 15, 30 and 60 minutes
following injection compared with control mice (Figure 4). The
corresponding glucose AUC over 120 minutes was significantly in
AAV5 Ex-4 mice in comparison to control animals (333.7614.2
vs. 378612.3 mM per minute; p,0.05).
No significant difference was observed in fasting glycaemia,
glycosuria or HbA1c values throughout the study. At the end of
the study, AAV5 Ex-4 mice showed significant lower fasting
insulin circulating levels and HOMA-IR index compared with
control animals (Table 2).
On the other hand, significant reductions in HbA1c levels and
glycosuria were observed in Zucker fa/fa rats. AAV5 Ex-4
treatment resulted in significantly lower HbA1c level as compared
with control animals (4.760.1 versus 5.060.1%; p,0.05).
Glycosuria was detected in 4 control rats 8 weeks after vector
administration. No glycosuria was reported in treated rats.
Accordingly to the low hypoglycaemic risk profile of Ex-4, no
significant difference in fasting glycaemia was observed between
treated and control rats during the study. Moreover, a statistically
significant difference in fasting insulinemia and HOMA-IR index
was detected between treated and control animals at the end of the
study (Table 2).
Discussion
GLP-1 RA are a very interesting therapeutic approach for the
treatment of T2DM, showing a remarkable efficacy on glycaemic
control and beneficial effects on body weight [39,40]. A phase II
clinical trial has shown the potential efficacy and safety of GLP-
1 RA in the treatment of obesity [41], although this disease is not
among the approved indication. Wider use of GLP-1 RA is
presently limited by their cost, and need for multiple subcutaneous
administration. Adenoviral and plasmid DNA mediated gene
therapy can direct the expression of GLP-1 RA in tissue not
physiologically intended for secretion [10–16] achieving long term
metabolic effects through high vector doses systemic administra-
tion either via intravenous or intraperitoneal injection. Both
systems demonstrated short-term efficacy on metabolic improve-
ment and required high vector doses and/or systemic administra-
tion. Recently, Voutetakis et al reported that an adenoviral-
mediated transduction of SG with a vector encoding GLP-1, can
induce short-term moderate reduction of blood glucose in a
murine model of diabetes [29]. Not surprisingly, although those
approaches were shown to reduce blood glucose, no effect on
HbA1c levels has ever been reported, confirming that the
therapeutic efficacy was not sustained.
Our study shows for the first time a sustained secretion of Ex-4
at pharmacological levels. These circulating levels are several fold
higher than reported for endogenous human GLP-1 after a meal
(40 pmol/l) [42] and Ex-4 steady-state values attained in human
clinical studies with 10 mg injected exenatide (50 pmol/l) [43].
This sustained Ex-4 secretion resulted in a significant reduction in
weight gain, which persisted throughout the study. The mecha-
nism underlying the effect of Ex-4 on body weight is still
controversial and likely related to a peripheral action on gastric
motility and/or a direct effect on the hypothalamic region
involved in the regulation of eating behaviour. Effects on daily
food intake between treated and control animals were detected
only transiently in rats, which showed a reduced meal size,
suggesting enhancement of satiety. It should be noted that
limitations on the accuracy of measuring food intake could have
prevented detection of a difference in food intake associated with
changes in body weight over the long-term.
A reduction of fasting insulin levels, together with an
improvement of HOMA insulin resistance index (based on fasting
insulin and glucose) was observed in treated rats and mice,
suggesting that Ex-4 secretion improves insulin sensitivity; this was
confirmed by the results of insulin tolerance test in HFD mice.
Although weight loss could explain the enhancement of insulin
sensitivity, a direct insulin-sensitizing effect of Ex-4 is also possible.
Alternatively, the improvement in insulin sensitivity could be due
to the inhibition of glucagon secretion.
Although the effect of Ex-4 expression on body weight could
have contributed to the improvement in glycaemic control, it is
very likely that direct action of Ex-4 on insulin and glucagon
secretion, and possibly insulin resistance, played a major role.
Furthermore, some limitations of present study should be
recognized. 14 week HFD mice and 17 week Zucker fa/fa rats are
more experimental model of obesity, and insulin resistance than
models of overt diabetes, as indicated by fasting glycemic values
throughout the study. Therefore, we performed the insulin
sensitivity test in the HFD mouse, because of its greater similarity
to polygenic pathogenesis of human obesity compared with Zucker
fa/fa rat. However, glycemic control was evaluated through
HbA1c (as a surrogate marker), for fasting glycemia and glycosuria
detection in both animal models.
This study suggests an alternative approach to delivering Ex-4 is
possible and can reduce weight gain as well as trigger improved
metabolic function in two animal models. Although Ex-4
expression has shown metabolic benefits there is concerns about
the long-term safety of this drug and its effect on inducing tumors
in rodents [44], which has not been reported in humans. This
affect maybe the result of the high bolus delivery of Ex-4 necessary
with injection delivery and is not observed with gene therapy
based delivery, which can maintain a constant level of expression.
Other studies have demonstrated that transgene expression in
rodents can last of the life of the animal following gene transfer to
several tissues including salivary glands [29]. Although, no adverse
effects of sustained expression were noted in either animal model
over the 2 month period of this study additional long-term studies
would support the long term safety of this drug.
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